Moderna says achieved 2024 product sales of $3B-$3.1B

“In 2024, we achieved $3.0 – 3.1 billion in product sales, approval of our RSV vaccine and continued to adapt our COVID-19 business for the endemic setting. At the same time, we reduced our cash operating cost by over 25 percent compared to 2023 and aim to reduce 2025 cash costs by $1 billion with a plan for an additional $500 million cost savings in 2026,” said Stephane Bancel, Chief Executive Officer of Moderna (MRNA). “We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the next three years, and reducing costs across our business.” 2024 financial updates: Moderna achieved 2024 product sales in the range of approximately $3.0 to 3.1 billion comprising $1.7 billion in the U.S. and $1.3 to 1.4 billion in Rest of World. This includes more than $3.0 billion in Spikevax sales and minimal sales from mRESVIA. Cash, cash equivalents and investments at year-end 2024 were approximately $9.5 billion.